DiaMedica Therapeutics
DMAC
26 hedge funds and large institutions have $3.14M invested in DiaMedica Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
9% less call options, than puts
Call options by funds: $10K | Put options by funds: $11K
4.32% less ownership
Funds ownership: 13.88% → 9.57% (-4.3%)
7% less funds holding
Funds holding: 28 → 26 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
58% less capital invested
Capital invested by funds: $7.42M → $3.14M (-$4.28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$26.4K |
| 3 |
HF
HRT Financial
New York
|
+$16.3K |
| 4 |
Jane Street
New York
|
+$15.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.38M |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$30K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$24K |
| 4 |
SC
Shay Capital
New York
|
-$20K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$17.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Stonepine Capital Management
Bend,
Oregon
| – | -$2.38M | -1,176,344 | Closed |
|
|
CF
27
Cantor Fitzgerald
New York
| – | -$30K | -14,691 | Closed |
|
|
SC
28
Shay Capital
New York
| – | -$20K | -10,000 | Closed |
|
|
PFGIA
29
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| – | -$2K | -1,300 | Closed |
|
|
NFSG
30
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$3K | -1,269 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | -$109 | -70 | -40% |
|
DMAC Hedge Fund Activity: Q3 2022 in Review
26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2022, worth a combined $3.14M — down 58% from $7.42M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMAC and 5 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $55.1K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.38M sold.
- 26 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2022, down from 28 in Q2 2022.
- Funds reported $3.14M of DiaMedica Therapeutics stock for Q3 2022, down 58% quarter-over-quarter.
- 5 funds opened new DiaMedica Therapeutics positions in Q3 2022 and 7 closed out, a net change of -2 holders.
- The largest DiaMedica Therapeutics buyer in Q3 2022 was Susquehanna International Group, an estimated $55.1K added.
- The largest DiaMedica Therapeutics seller in Q3 2022 was Stonepine Capital Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q3 2022.